ReviewMetabolic brain disease2026
From glycemic control to neuroprotection: alogliptin as a repurposed candidate for Huntington's disease.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric disturbances, for which no disease-modifying therapies are currently available. Emerging evidence implicates metabolic impairment, mitochondrial dysfunction, oxidative stress, and neuroinflammation as central contributors to HD pathogenesis, thereby highlighting novel avenues for therapeutic intervention beyond conventional strategies. In this context, drug repurposing has gained considerable attention as an efficient approach to accelerate therapeutic development. Alogliptin has multiple complementary mechanisms of action that exert neuroprotective effects through inhibition of DPP-4 to boost endogenous incretin signaling (especially GLP-1), inhibition of inflammatory pathways, inhibition of oxidative stress, preservation of mitochondrial function, and modulation of neuronal survival signaling. The review summarizes existing data on the contribution of the incretin signaling to neuroprotection and critically analyzes the mechanism through which alogliptin might regulate important pathological events in HD, such as apoptosis, oxidative stress, and neuroinflammation. Additionally, preclinical results and pharmacological properties in favor of its translational potential are presented, as well as the reflection on its clinical usage and additional research perspectives. Even though direct evidence in HD is not extensive, the overlap of metabolic and neurodegenerative pathways offers a strong argument to study. This review identifies alogliptin as a potent repurposable agent and the necessity to conduct specific experimental and clinical research to determine its effectiveness in refining symptoms and changing the disease course in HD. This narrative review critically evaluates the available experimental evidence supporting the repurposing potential of Alogliptin for HD.
Indexed as
Identifiers
42474536What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.